ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

GSK and Ideaya seal synthetic lethality pact

by Lisa M. Jarvis
June 20, 2020 | APPEARED IN VOLUME 98, ISSUE 24

GlaxoSmithKline will pay Ideaya Bioscience $100 million to gain access to three cancer drug–discovery programs. The deal, which includes an equity stake in the biotech worth $20 million, centers on finding drugs that exploit the concept of synthetic lethality, wherein a cancer cell can survive without one gene but dies if a second gene is crippled. GSK is buying into three synthetic lethality targets—MAT2A, Pol Theta, and Werner Helicase—for which Ideaya says it has solved crystal structures and made preclinical progress.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment